28/05/2016 00:03:34 1-888-992-3836 (toll free) Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
05/19/20164:56PMGLOBEMyriad Genetics’ Statement on HIPAA Complaint from Four Patients
SALT LAKE CITY, May 19, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. ... More...>>
05/18/20165:57PMGLOBEMyriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Informa...
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas... More...>>
05/18/20165:05PMGLOBEMyriad to Present New Research at the 2016 ASCO Annual Meeting
SALT LAKE CITY, May 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill.  Key podium presentations will... More...>>
05/11/20167:05AMGLOBECrescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis
myVectraTM Enables Secure Access to Vectra® DA Test Results SOUTH SAN FRANCISCO, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that it has launched a new web-based portal called myVectra for patients with rheumatoid arthritis... More...>>
05/06/20167:05AMGLOBEMyriad to Present Three New Studies at the AUA Annual Meeting
SALT LAKE CITY, May 06, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies will be featured at the American Urological Association annual meeting, which will take place May 6-10 in San Diego, Calif. ... More...>>
05/03/20164:05PMGLOBEMyriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
Total Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and Updates Fiscal Year 2016 Financial Guidance   SALT LAKE CITY, May 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial results for its fiscal third-quarter... More...>>
05/02/20167:05AMGLOBEMyriad Genetics to Present at the Bank of America Health Care Conference
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that R. Bryan Riggsbee, chief financial officer, Myriad Genetics, is scheduled to present at the 2016 Bank of America  Healthcare Conference at 3:40 p.m. PDT (6:40 pm EDT) on May 11, 2016, at the Encore at Wynn in... More...>>
04/28/201611:46AMGLOBEMyriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3
SALT LAKE CITY, April 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 3.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
04/14/20167:05AMGLOBEMyriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting
SALT LAKE CITY, April 14, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company and its scientific collaborators will present two studies at the American Association for Cancer Research annual meeting, April 16-20, in... More...>>
03/30/20167:05AMGLOBEMyriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing ...
SALT LAKE CITY, March 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency... More...>>
03/21/20167:05AMGLOBEMyriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing
SALT LAKE CITY, March 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, and Access Health®, an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear... More...>>
03/18/20167:05AMGLOBEThe Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Canc...
SALT LAKE CITY, March 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two important new studies at the 2016 Society for Gynecologic Oncology annual meeting in San Diego, Calif.  The data demonstrate the ability... More...>>
03/15/20167:05AMGLOBEMyriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test
SALT LAKE CITY, March 15, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the myPath® Melanoma test at the 2016 USCAP Annual Meeting in Seattle, Wash. “There is... More...>>
03/09/20167:46PMGLOBEMyriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  today announced that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Barclays Capital 2016 Global Healthcare Conference at 2:35 p.m... More...>>
03/09/20167:46PMGLOBEMyriad Advances Proprietary myVision® Variant Classification Tools to a Broader Range of Cancer Risk Genes
SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present new data on its proprietary variant classification program that is used to classify variants in cancer risk genes.  The study will be... More...>>
02/22/20167:05AMGLOBEMyriad Expands Diagnostic Research Collaboration With TESARO and Merck
SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational... More...>>
02/02/20164:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
Total Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance SALT LAKE CITY, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN... More...>>
01/21/20164:05PMGLOBEMyriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2
SALT LAKE CITY, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb. 2.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee... More...>>
01/07/20167:05AMGLOBEMyriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium
SALT LAKE CITY, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data will be highlighted on prostate and renal cancers at the 2016 ASCO Genitourinary Cancers Symposium, January 7-9, in San Francisco, Calif. ... More...>>
01/04/20165:00PMGLOBEMyriad Genetics to Present at the 34th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 34th annual J.P. Morgan Healthcare Conference at 9:30 a.m. PST (12:30 pm EST) on January 11, 2016, at the Westin St. Francis in San... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160528 04:03:36